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Pharmacodynamic analysis of the furosemide-probenecid inter-
action in man. Probenecid pretreatment in man increased the
overall response to furosemide in contrast to animal studies in
which probenecid decreased response by inhibiting proximal
renal tubular secretion of furosemide to its active site. We ad-
ministered i.v. 40 mg of furosemide to eight normal volunteers
with and without probenecid pretreatment and measured serum
and urinary furosemide concentrations by high performance liq-
uid chromatography to determine the mechanism of proben-
ecid' s effect. Probenecid pretreatment significantly increased
serum furosemide concentration. Urinary furosemide excretion
rate paralleled urinary sodium excretion rate; both were initially
decreased but were later increased by probenecid pretreatment.
Probenecid pretreatment decreased renal and nonrenal clearance
of furosemide (1.04 0.31 vs. 0.29 0.06 mllkg/min, P <0.05;
and 1.00 0.18 vs. 0.27 0.03 mllkglmin,P <0.004, respective-
ly). Although probenecid inhibited renal clearance for the dura-
tion of the study, accumulation of furosemide in serum from con-
comitant effects on nonrenal clearance allowed more furosemide
to appear in the urine at later times, increasing response. This
analysis demonstrated the importance of probenecid' s effects on
nonrenal elimination of furosemide in determining the overall re-
sponse to furosemide. The relationship between furosemide con-
centrations and response depicted a sigmoid dose-response
curve. Probenecid shifted the serum dose-response relationship
to the right but did not affect the relationship between urinary
furosemide excretion rate and response, demonstrating the im-
portance of the urinary (as opposed to serum) concentration-re-
sponse relationship of furosemide in normal man. This relation-
ship will provide a valuable tool for assessing response to diuret-
ics in various disease states where resistance to diuretics occurs.
Analyse pharmacodynamique de l'interaction furosémide-pro-
bénécide chez l'homme. Le pré-traitement par le probénecide
chez l'homme augmente Ia réponse globale au furosémide par
opposition aux etudes chez l'animal oü le probénecide diminue
cette reponse en inhibant Ia sécrétion tubulaire proximate de fu-
rosémide. Nous avons administré iv. 40 mg de furosémide par
voie a huit volontaires normaux, avec ou sans pré-traitement par
le probenécide, et mesuré les concentrations de furosémide sé-
riques et urinaires par chromatographie liquide a haute résolu-
tion afin d'étudier le mécanisme de l'effet du probénécide. Le
pré-traitement par le probénécide augmente significativement la
concentration sérique de furosémide. L'excrétion urinaire de fu-
rosémide est parallèle a l'excrétion urinaire de sodium. Ces deux
derniêres sont initialement diminuées mais ultérieurement aug-
mentées par le pre-traitement au moyen de probenécide. Le pre-
traitement par le probénécide diminue les clearances rénale et
non-rénale du furosémide (1,04 0,31 vs. 0,29 0,06 mI/kg/mm,
P <0,05; et 1,00 0,18 vs. 0,27 0,03 mllkglmin, P < 0,004,
respectivement). Bien que le probénécide diminue la clearance
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rénale pendant la durée de l'étude, l'accumulation sérique de
furosémide due aux effets sur Ia clearance non rénale permet
l'apparition dans l'urine de quantités plus importantes a des
temps ultérieurs, ce qui augmente la réponse. Cette analyse dé-
montre l'importance des effets du probenécide sur l'elimination
non rénale de furosémide dans le déterminisme de la réponse
globale au furosémide. La relation entre les concentrations de
furosémide et la réponse décrit une courbe dose-réponse sig-
moide. Le probénecide deplace la courbe dose-réponse sérique
vers Ia droite mais n'affecte pas Ia relation entre l'excrétion un-
naire de furosémide et la réponse, ce qui démontre l'importance
de Ia relation entre la concentration urinaire (a Ia difference de la
concentration serique) et la réponse. Cette relation fournit un
instrument utile pour évaluer Ia réponse aux diuretiques dans
divers états oü Ia résistance a ces drogues est observée.
Furosemide is one of the most potent and fre-
quently used diuretics [1—3]. Although its clinical ef-
fectiveness has been well established from prior
studies, pharmacokinetic and dynamic correlates
have only recently been investigated [4-7]. The new
development of a specific and sensitive assay for fu-
rosemide has made it possible to probe the determi-
nants of the response to furosemide and to better
understand the pharmacology of the drug, which, in
turn, may allow use of measures of the drug as a
probe of the pathophysiology of renal salt and water
metabolism.
Furosemide inhibits active chloride transport
throughout the thick ascending limb of the ioop of
Henle, also preventing the reabsorption of sodium
which passively follows chloride [8-10]. Studies
with microperfusion of isolated segments of renal
tubules [11] showed that furosemide's site of action
is at the luminal side of the nephron. Because fu-
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rosemide is an organic acid [2] and is highly bound
to serum proteins [12, 13], it gains access to its site
of action by secretion at the proximal tubule at the
nonspecific transport pathway for organic acids [14,
15]. Prior studies in animals have shown that
coadministration of probenecid, an organic acid
which competes for secretion, decreased furose-
mide secretion by the proximal tubule of the neph-
ron and decreased the amount of furosemide avail-
able at its site of action. Intravenous administration
to dogs of 50 mg/kg of probenecid over 5 mm com-
pletely attenuated the response to intraarterial in-
fusion of 1 g/kg/min of furosemide [16]. In con-
trast, our laboratory recently showed in normal vol-
unteers that pretreatment with probenecid caused
an increased response to 40 mg of furosemide ad-
ministered intravenously [17]. Sodium excretion
over 8 hours increased from 262 16 to 358 11
mEq (P < 0.005). The time course of this effect
showed that the initial response to furosemide was
decreased by probenecid, but after 1 to 2 hours,
probenecid caused an increased response to the di-
uretic; the overall effect was an increased total
amount of sodium excreted over 8 hours. These
data suggested a more complex interaction in man
between probenecid and furosemide than had been
described in experimental animals.
In the present study, we determined the mecha-
nism by which probenecid increased the natriuretic
effect of furosemide, and in so doing, established a
relationship between urinary concentrations of fu-
rosernide and natriuretic effect for this population of
normal volunteers.
Methods
Study protocol. We studied eight subjects, three
women and five men, who were 22 to 27 years old.
Subjects had normal medical histories, physical ex-
aminations, and screening blood chemistries, blood
counts, and urinalyses. Each subject was fully in-
formed of the nature of the study and signed an in-
formed consent approved by the Committee on Hu-
man Research at the University of Texas Health
Science Center at Dallas.
This paper reports results of those studies assess-
ing the mechanism and the pharmacodynamics of
the probenecid-furosemide interaction. These sub-
jects were studied a total often times each with sev-
eral different diuretic regimens, all of which were
conducted in random order and with an interval of
at least 1 week between each phase of the study.
The effect of probenecid on the response to furose-
mide has been published [17].
In this report, we analyzed the results of studies
after intravenous administration over 2 to 3 mm of
40 mg of furosemide with and without pretreatment
with probenecid, and control studies with adminis-
tration of no drug and with probenecid alone. Sub-
jects ingested 1 g of probenecid at bedtime the night
before and on arising the morning of the study (30 to
60 mm before administration of furosemide).
Subjects had ingested a diet containing 150 mEq
of sodium and 60 to 80 mEq of potassium per day
for 3 days as outpatients on the General Clinical Re-
search Center. They collected a 24-hour urine
sample beginning the morning of the third day to
assess adherence to the diet. The sodium content of
this 24-hour urine specimen was not significantly
different before any of the phases of the study (0.09
0.015 and 0.10 0.017 mEq/min before furose-
mide alone and with probenecid, respectively). The
study began on the morning of the fourth day at the
close of the 24-hour urine collection. The day of the
study, patients skipped breakfast (including caf-
feine containing beverages) but ate lunch (at least 3
hours after the start of the study).
Heparinized scalp-vein needles were placed in
each forearm, one for administration of furosemide
and replacement fluids and one for obtaining blood
samples. Blood samples were drawn at 0, 5, 10, 20,
30, 45, 60, 80, 100, 120, 180, 240, 300, 360, 480 mm,
and 24 hours after administration of furosemide. All
urine was collected by spontaneous voiding at 0.5,
1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours. During the first 2
to 3 hours of the study, urine output was replaced
by isovolumic amounts of lactated Ringer's solution
administered by vein over the time interval of the
subsequent collection period. When urine output
had decreased to approximately 250 mllhr, fluids
were administered orally. In the control studies, all
urine losses were replaced orally. No changes oc-
curred in serum sodium, potassium, chloride, or
creatinine in any study. Creatinine clearance did
not change throughout the study. Consequently, we
elected to express response as sodium excretion
rate in milliequivalents per minute.
Assays. The assay for concentrations of furose-
mide in urine and in serum samples was performed
with a Waters model ALC-GPC-204 high-perform-
ance liquid chromatograph equipped with a Waters
model 440 dual wavelength detector and a dual
channel 10-mV Omniscribe recorder (Waters Asso-
ciates, Inc., Milford, Massachusetts 07157). The
separation was effected with a 30 cm x 4 mm re-
verse-phase "s Bondapak C18" column (Waters
Assoc.) which was eluted at 2.0 mllmin with an
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acetonitrile/water (23/77 by volume) solution buf-
fered to pH 3.8 with 0.01 M acetate. The assay for
furosemide in studies where probenecid was admin-
istered was changed from the "normal" furosemide
assay (25/75 by volume acetonitrile/water at pH 4.0
to 4.5) to separate the furosemide and phenobarbital
(the internal standard) peaks from interfering peaks
due to probenecid and its metabolites. The column
effluent was monitored simultaneously at 280 nm for
furosemide absorption and at 254 nm for phenobar-
bital.
Urine samples were forced through a 0.5-p sy-
ringe filter, and 50 pJ of urine was then pipetted into
a test tube containing 0.2 ml of water and 50 pi of a
standard phenobarbital solution (0.40 mg/ml). The
solution was mixed well, and 10 to 20 pl were inject-
ed onto the column.
Serum samples were prepared by pipetting 0.2 ml
of serum and 10 pi of phenobarbital standard into a
test tube; 0.4 ml of acetonitrile was added to precip-
itate serum proteins, and the mixture was centri-
fuged for 10 mm. The supernate was poured off, and
the acetonitrile was evaporated with a gentle stream
of nitrogen. The remaining residue from this evapo-
rated supernate was reconstituted with 50 l of the
mobile phase, and 10 to 20 j.d were injected onto the
column.
Prior to each series of patient samples, known so-
lutions containing given amounts of phenobarbital
standard and varying amounts of furosemide stan-
dard were injected onto the column, and a standard
curve was constructed by plotting the furosemide/
phenobarbital peak height ratios (F/P) against the
amount of furosemide in each standard sample. The
amount of furosemide in patient samples was ob-
tained by using the measured F/P ratio in a linear
regression program to calculate the actual amount
of furosemide in that specific patient sample by
comparison to the standard curve. A standard curve
is depicted in Fig. 1, and a typical trace of the chro-
matographic separation of a representative urine
specimen is shown in Fig. 2. Trace A occurred with
furosemide administration alone, and trace B oc-
curred with coadministration of probenecid and fu-
rosemide. The additional peaks in trace B presum-
ably represent probenecid and its metabolites. Ten
determinations of standard serum samples at three
different concentrations of furosemide were 0.0572
0.0015, 0.2913 0.002, and 0.896 0.006 for
concentrations of approximately 0.06, 0.3, and 0.9
j.tg/ml, respectively.
Creatinine was measured in serum and urine with
a Technicon autoanalyzer. Sodium and potassium
[F] p1 F, mm P, mm F/P
2
5
7
10
15
20
0.90
1.95
2.80
4.00
5.50
7.10
5.50
5.35
5.50
5.30
4.95
4.80
0.16
0.36
0.51
0.75
1.11
1.48
r
m
= 0.9998
0.074
b = 0.005
were measured with an Instrument Laboratories
model 143 flame photometer. Chloride was mea-
sured with a Buchler chloridometer, model 4-2500.
Data analyses. Following intravenous adminis-
tration, serum furosemide concentration vs. time
curves appeared to be described by a two-com-
partment pharmacokinetic open model of the for-
mat:
CP = Ae_at + Bet
where Cp is serum concentration at time t, A and B
are constant coefficients or "intercepts," and a and
/3 are fast and slow disposition rate constants. Data
were analyzed by computer fitting using a nonlinear
least squares program (NONLIN) [18]. The degree
of fit of the data to the model was evaluated by ex-
amining r2, the proportion of the variance in the
data which is explained by the model [19]. The
plasma clearance was defined as the dose adminis-
tered divided by the total area under the plasma
concentrations vs. time curve. Renal clearance was
obtained for each study by plotting the plasma fu-
1.5
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Fig. 1. Typical standard curve for assay of furosemide relating
the ratio of heights of peaks offurosemide (F) to heights of peaks
ofphenobarbital (P) (the internal standard) versus concentration
offurosemide ([F]). r denotes the correlation; m, the slope; and
b, the y-intercept which should not differ from zero.
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Fig. 2. Representative chromatographic tracing of a urine specimen after furose-
mide alone (A) and after furosemide plus probenecid (B). The additional peaks in
trace B represent probenecid and its metabolites (unlabeled).
rosemide concentration at the midpoint of a urine
collection period vs. urinary furosemide excretion
rate. This plasma furosemide concentration was de-
termined from the computer-calculated curve fitting
the plasma furosemide data. Renal clearance is the
slope of this plot derived as the least squares line
regressed through the origin [20]. The intercepts of
least squares linear regressions not forced through
the origin were tested against zero [21] and were not
significantly different from zero. Nonrenal clear-
ance was defined as the difference between plasma
clearance and renal clearance. These parameters
were analyzed as the mean obtained from fitting of
data from individual studies. When the parameters
were obtained from fitting the meaned data, results
did not differ significantly.
Significance of differences was tested with paired
t tests. All significant differences in this report have
P values of <0.05. Group data are expressed in
standard renal physiologic and pharmacokinetic
terms as mean SEM.
Results
Figure 3 shows the effect of probenecid on the
serum concentration of furosemide for all subjects
after administration of 40 mg of furosemide intra-
venously. Fitting these curves to a two-com-
partment pharmacokinetic model resulted in an r2 of
0.995 and 0.993 (with and without probenecid pre-
treatment, respectively). It is apparent from Fig. 3
that pretreatment with probenecid significantly in-
creased serum furosemide concentrations. The
elimination half-life of furosemide, determined as
the mean of analyses of each study, increased from
105.4 16.4 to 168.9 15.1 mm (P < 0.033). Deriv-
ing these parameters from curves fit to mean data
gave similar results. These elimination half-lives are
longer than those previously reported [4, 5, 7, 22].
We followed concentrations of furosemide for long-
er periods of time. By so doing, the elimination
phase was more clearly defined and resulted in a
longer elimination half-life. Examination of the time
course of probenecid's effect showed that initial fu-
rosemide concentrations were not significantly dif-
ferent, but after 30 mm probenecid caused per-
sistently higher serum concentrations of furose-
mide. The plasma clearance of furosemide de-
creased after probenecid pretreatment from 2.04
0.42 to 0.56 0.05 mi/kg/mm (P < 0.011). The
volume of distribution at steady state was not
changed by probenecid, 0.110 0.015 and 0.161
0.05 1 liter/kg (P 0.346) with and without pro-
benecid pretreatment, respectively. Consequently,
the effect of probenecid occurred by decreasing the
elimination of the drug rather than by affecting the
volume in which it distributes.
Probenecid could affect the pharmacokinetics
and dynamics of furosemide by changing its binding
to serum proteins. Binding of furosemide to serum
proteins, however, remains the same over the con-
U-
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Time, mm
Fig. 3. Effect of probenecid pretreatment on the serum concentration ([F]) over
time after ad,ninistration i.v. of 40 ,ng offurosemide. Closed symbols represent
furosemide alone. Open symbols represent furosemide plus probenecid. The lines
represent curves computed by iterative least squares fitting of the data. Brackets
represent SEM.
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centrations of furosemide attained in this study, and
probenecid does not affect extent of binding [13,
23].
The effects of probenecid pretreatment on urinary
furosemide excretion rate (upper curves) and on re-
sponse to furosemide expressed as urinary sodium
excretion rate (lower curves) are shown in Fig. 4.
After probenecid pretreatment, the initial furose-
mide excretion rate was significantly decreased (P
< 0.026). After approximately 60 mm, however,
probenecid pretreatment caused an increased uri-
nary excretion rate of furosemide. The effect of
probenecid on the natriuretic response to furose-
mide shown in the lower part of Fig. 4 parallels the
urinary excretion rate of furosemide. The initial uri-
nary excretion rate of sodium after pretreatment
with probenecid was less than that with furosemide
alone, but after approximately 60 mm the response
with probenecid pretreatment became significantly
higher. Although the initial decrement in urinary so-
dium excretion rate does not reach statistical signif-
icance, the P value is equal to 0.053.
Fig. 5 shows the relationship between serum fu-
rosemide concentration and urinary furosemide ex-
cretion rate. Each point in the figure represents the
mean of observations in one collection period for all
subjects. Probenecid pretreatment decreased renal
clearance of furosemide determined as the slopes of
these plots from 63.8 15.6 to 20.6 5.2 mllmin
(P < 0.036). The renal clearance of furosemide, fac-
tored by body weight, decreased from 1.04 0.31
Time, mm
Fig. 4. Time course of the natriuretic response (lower pair of
curves) and urinary excretion rate of furosemide (upper pair of
curves) with and without probenecid pretreatment. Symbols are
as in Fig. 3. Absence of brackets implies a SEM within the area of
the symbol.
to 0.29 0.06 mi/kg/mm after probenecid pre-
treatment (P < 0.05). Probenecid also significantly
decreased nonrenal clearance of furosemide from
1.00 0.18 to 0.27 0.03 mlfkg/min (P < 0.004).
The effect of probenecid on renal clearance was
prolonged and persisted throughout the study, as in-
dicated in Fig. 6.
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The results of this study clarify the mechanism by
which pretreatment with probenecid increased the
response to furosemide as described in an earlier
report from our laboratory [17]. In addition, this
•
study verified the heretofore assumed hypothesis
derived from studies in animals that furosemide in-
hibits chloride transport from the luminal rather
than the peritubular surface of the nephron [11], and
that secretion of furosemide into the lumen at the
proximal tubule is a prerequisite for its diuretic ac-
tion [10].
These same mechanisms also apply to other or-
ganic acid diuretics such as thiazides [24] and eth-
acrynic acid [25]. Several studies in animals showed
that probenecid attenuated the natriuretic effect of
Serum furosemide (Cpl, pg/mi chlorothiazide [24, 26-28] and of furosemide [16,
Fig. 5. Relationship between urinary excretion rate and serum 29], presumably by competing with and decreasing
concentration after intravenous administration of40 mg offu-
rosemide. Symbols are as in previous figures. The lines represent
linear least squares regressions of the data. Their slopes (m) rep-
resent renal clearance of furosemide.
diuretic transport at the organic acid secretory path-
. .
way [30]. Similar studies in man, however, did not
support the findings from in vitro and in vivo animal
studies [7, 17, 31-33]. Several possible mechanisms
might explain the difference in response between
120
man and experimental animals.
The present study clarified the mechanism of the
100
complex interaction between probenecid and fu-
rosemide in man in which probenecid caused an mi-
o 80 tial decrease followed by a later increase in re-
sponse [17]. This effect could have occurred by a
60
c1
changing effect of probenecid on delivery of furose-
mide to its site of action in which an initial inhibition
D 40 of transport of furosemide dissipated as probeneciditself was eliminated, allowing more furosemide to
20
-
-.- be transported to its active site at later times.
Probenecid, however, caused a persistent decrease
0 100 200 300 400
Time, mm
Fig. 6. Effect of probenecid on renal clearance (UFV/Cp) of fu-
rosemide over time. Symbols are as in previous figures.
Figure 7 depicts dose-response" curves for con-
centrations of furosemide in serum and urine re-
lated to natriuretic effect. Probenecid caused a sig-
nificant shift to the right of the relationship between
serum concentration of furosemide and sodium ex-
cretion rate; in contrast, the relationship between
urinary concentration of furosemide and sodium ex-
cretion rate was not affected by probenecid pre-
treatment. This finding verifies the previously as-
sumed hypothesis that urinary concentrations of fu-
rosemide rather than concentrations in serum best
reflect concentrations of diuretic reaching its site of
action.
in furosemide secretion and in renal clearance (Fig.
6). Importantly, probenecid suppressed nonrenal as
well as renal clearance of furosemide. This long
lasting, dual effect of probenecid on nonrenal and
renal elimination of furosemide, rather than a
changing effect of probenecid on renal clearance
over time, caused amounts of furosemide appearing
at the active site to change through the time course
of the study. Probenecid's concomitant inhibition of
nonrenal clearance (probably hepatic) allowed ac-
cumulation of sufficient amounts of furosemide in
serum at later times to cause greater amounts of fu-
rosemide to be delivered into the urine despite con-
tinued suppression of renal clearance. This phe-
nomenon had not been observed in animal studies,
because furosemide was administered into the renal
artery and no ramifications of probenecid's effect
on nonrenal clearance of furosemide could be ob-
served. Consequently, pharmacodynamic analysis
of the interaction between furosemide and proben-
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ecid indicates that the mechanism of renal handling
of furosemide appears to be uniform among the spe-
cies studied.
Two other important aspects of renal pharmacol-
ogy were demonstrated in this study. First, the ef-
fects of probenecid on organic acid transport were
long-lasting. A constant degree of inhibition was ob-
served for up to 6 hours. The relationship between
the time course of this effect and the kinetics of
probenecid and/or its metabolites cannot be deter-
mined from this study but are consistent with prior
studies of the time course of the inhibitory effect of
probenecid on transport of other organic acids [33,
34].
Second, our data clearly demonstrate that the
amount of furosemide delivered into the urine is
more directly correlated to response than is serum
concentration of furosemide. This fact is dramati-
cally illustrated in Fig. 7. Probenecid caused a sig-
nificant shift to the right of the relationship between
serum concentration and response but caused no
change in the relationship between concentration of
furosemide in urine and response. This analysis
confirms in vitro and in vivo animal studies showing
that probenecid interferes with renal tubular secre-
tion of furosemide but not with furosemide action at
its active site. A similar phenomenon appears to oc-
cur in moderate renal insufficiency in which an ac-
cumulation of endogenous organic acids decreased
furosemide secretion and, consequently, decreased
response to furosemide [35, 36]. In such conditions,
urinary furosemide excretion predictably would
better correlate with diuretic response than would
serum concentration of furosemide.
It is clear from Fig. 7 that the relationship be-
tween furosemide concentration and response is not
linear but follows the "typical" sigmoid shape of a
dose-response curve. Other investigators have
graphically demonstrated a similar nonlinear rela-
tionship between concentrations of furosemide [6,
7] and piretanide [37] in serum and response. The
investigators concluded, however, that the re-
sponse was linear [6, 7] or did not define the upper
plateau of the relationship [37]. Additionally, the
importance of furosemide in the urine compared to
serum has not been demonstrated. An implication
of this analysis is that studies of the relationship be-
tween the pharmacokinetics and the pharma-
codynamics of furosemide (and presumably other
diuretics) cannot a priori assume a linear relation-
ship and must include data assessing the spectrum
of the dose-response curve. For example, the at-
tainment of an upper plateau in response most likely
accounts for reports that a number of normal sub-
jects failed to show an increase in overall response
with higher doses of furosemide [38].
In addition, in this study probenecid increased re-
sponse without affecting the total amount of furose-
mide reaching the urine (19.67 2.21 and 16.03
1.45 mg/8 hr) before and after probenecid pre-
treatment, respectively (P 0.252). Therefore,
probenecid increased the overall response to fu-
rosemide by affecting the time course of delivery of
furosemide to its site of action such that concentra-
tions of furosemide in urine after probenecid pre-
treatment were more often at the "steep" portion of
the dose-response curve than after furosemide
alone. Attaining this steep portion of the dose-re-
sponse curve in patients treated with diuretics
would be an important determinant of the most effi-
cacious dosing regimen in an individual patient. Ap-
plication of this approach to treating patients resis-
tant to diuretics warrants further study.
Summary. Probenecid alters the pharmacokinet-
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Fig. 7. "Dose-response" curves for furosemide after a 40mg intravenous dose.
The left panel depicts the relationship between concentrations of furosemide in
serum and response expressed as sodium excretion rate. The right panel depicts
the relationship between the urinary excretion rate of furosemide and response.
Symbols are as in previous figures.
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ics of furosemide in man and causes an increase
in natriuresis in contrast to the decreased response
observed in animal studies. Our data are con-
sistent with the tenet that furosemide acts at the
luminal side of the nephron, and we have shown
that urinary furosemide rather than serum furose-
mide concentrations should be used in assessing the
diuretic response. It is also clear that the relation-
ship between furosemide concentration and natriur-
esis is not linear through the range of concentra-
tions achieved in man. This relationship probably
also holds for other diuretics, and the full range of
the dose-response curve must be considered in as-
sessing the determinants of the response to a diuret-
ic. This relationship, now well characterized in nor-
mal man, should provide a valuable tool in assess-
ing response to diuretics in various disease states in
which resistance to diuretics occurs.
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